P01.21: Screening for Down syndrome by fetal nuchal translucency and chorionic villus sampling in a high risk population

Nuchal translucency measurement in first trimester Down syndrome screening.

(1) Approximately three in every four fetuses with Down syndrome have increased nuchal translucency (NT), which is a larger than normal build-up of fluid at the back of the neck. (2) The ultrasound measurement of NT between 11 and 14 weeks' gestation, in combination with the mother's age and the levels of placental biochemical markers in her blood, can be used to detect approximately 84% of fet...

Nuchal translucency and first trimester biochemical markers for Down syndrome screening: a cost-effectiveness analysis

Nuchal translucency and first trimester biochemical markers for Down syndrome screening: a cost-effectiveness analysis

Nuchal translucency and first trimester biochemical markers for Down syndrome screening: a cost-effectiveness analysis

Nuchal translucency and first trimester biochemical markers for Down syndrome screening: a cost-effectiveness analysis